Apollon Formularies - Apollon Jamaica Open with COVID-19 Certification
RNS Number : 0113A
Apollon Formularies plc
27 May 2021



27 May 2021

Apollon Jamaica Open with COVID-19

Certification of Negril Facility


Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company") is pleased to announce that the  facility and operation located in Negril, Jamaica, of Apollon Formularies Jamaica Limited ("Apollon Jamaica"), where the medical cannabis dispensary and treatment centre are situated, has passed all requirements and received COVID-19 Health and Safety Protocols Certification and is treating patients.  

The Tourism Product Development Company Ltd. (TPDCo), an agent for the Government of Jamaica, recently performed a COVID-19 compliance assessment that involved the health and safety of the Negril, Jamaica location where Apollon Jamaica and the adjacent Doc's Place Wellness Centre are operated. A certification of compliance for that location was received through Doc's Place from Ms. Kimberley Blackwood, COVID-19 Protocol Compliance Manager for TPDCo, recognizing the compliance of those facilities and operations with COVID-19 Health and Safety Protocols.

Stephen D. Barnhill, M.D., CEO of Apollon Formularies plc, commented, "We are very proud of our Jamaican team for successfully passing all requirements leading to this Certification. Since receiving this government required certification, Apollon Jamaica is again seeing patients at our pre-COVID levels. The health and safety of our patients are our primary concern, especially for those who are very ill and suffering. Having TPDCo Certification allows us to receive medical tourist patients and better enable all patients to have access to needed medical cannabis treatments."  

In response to COVID-19, the Government of Jamaica tasked the Ministry of Health & Wellness (MoHW), Ministry of Tourism (MoT) and the Tourism Product Development Company Limited (TPDCo) to develop health and safety protocols in order to provide consistent standards to keep workers, patients, local communities and tourists safe from risks related to COVID-19, caused by the virus Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2).

For centres and service providers involved with medical treatment and medical tourism, the principal objective was to enable patients to safely continue to get access to their regular medical care needs even during a global pandemic. The protocols established included all manner of health and safety considerations, including facility and equipment cleaning, person-to-person distancing and mask wearing, use and discard of disposal materials, online treatment scheduling, and digital healthcare information gathering and record keeping. TPDCo was tasked with certifying and monitoring the compliance of organizations with the established protocols. 

Paul Burke, CEO of Apollon Jamaica, commented, "Apollon Jamaica works diligently every day to ensure that its medical cannabis treatment facilities and operations meet COVID-19 Health and Safety Protocols. We want our patients to know that, whether they are local to Jamaica, or have travelled internationally to Jamaica, Apollon Jamaica will provide them with a safe and COVID-19 compliant environment for their treatment."

The directors of the Company accept responsibility for the contents of this announcement.

- End -

For additional information, please visit www.apollon.org.uk or contact:

Apollon Formularies                                                     

Tel:                                         +44 207 907 9314

Stene Jacobs                         stene@apollon.org.uk 


Peterhouse Capital Limited (Corporate Adviser)             

Tel:                                         +44 207 220 9795

Guy Miller                             gm@peterhousecapital.com


Blytheweigh (Financial PR/IR-London)                 

Tel:                                         +44 207 138 3204

Tim Blythe                             tim.blythe@blytheweigh.com

Megan Ray                            megan.ray@blytheweigh.com 


About Apollon and Apollon Jamaica

Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica Limited is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to cultivate, perform research and development, process, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision. Apollon and Apollon Jamaica are parties to a Commitment Agreement whereby Apollon is entitled to 95% of Apollon Jamaica's Net Profits, and per a Stock Pledge Agreement that includes Stephen D. Barnhill, M.D., Apollon is to be assigned the entire 49% equity interest of Apollon Jamaica held by Dr. Barnhill, which is the maximum interest in a medical cannabis company allowed to be held by a non-Jamaican, upon the CLA approving the assignment.

About TPDCo

The Tourism Product Development Company Ltd. (TPDCo - www.tpdco.org) is the central agency mandated by the Government of Jamaica to facilitate the maintenance, development and enhancement of the tourism product. It is designed to support government and quasi-government agencies in the development of the tourism industry, particularly by coordinating and facilitating prompt action between public and private sector interests.

Disclaimer & Reader Advisory

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "may", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.